In vitro and ex vivo models for evaluating vaginal drug delivery systems

被引：19
|
作者：
Shapiro, Rachel L. [1 ,2 ]
DeLong, Kevin [1 ,3 ]
Zulfiqar, Fareeha [1 ,3 ]
Carter, Davell [1 ,4 ]
Better, Marina [1 ,4 ]
Ensign, Laura M. [1 ,3 ,4 ,5 ,6 ,7 ,8 ,9 ]
机构：
[1] Johns Hopkins Univ, Wilmer Eye Inst, Sch Med, Ctr Nanomed, 400 N Broadway, Baltimore, MD 21231 USA
[2] Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA
[3] Johns Hopkins Univ, Wilmer Eye Inst, Dept Ophthalmol, Sch Med, 1800 Orleans St, Baltimore, MD 21287 USA
[4] Johns Hopkins Univ, Dept Pharmacol & Mol Sci, Sch Med, 725 N Wolfe St, Baltimore, MD 21287 USA
[5] Johns Hopkins Univ, Dept Chem & Biomol Engn, 3400 N Charles St, Baltimore, MD 21218 USA
[6] Johns Hopkins Univ, Sch Med, Dept Gynecol & Obstet, 1800 Orleans St, Baltimore, MD 21287 USA
[7] Johns Hopkins Univ, Sch Med, Dept Infect Dis, 1800 Orleans St, Baltimore, MD 21287 USA
[8] Johns Hopkins Univ, Sch Med, Dept Oncol, 1800 Orleans St, Baltimore, MD 21287 USA
[9] Johns Hopkins Univ, Dept Biomed Engn, 3400 N Charles St, Baltimore, MD 21218 USA
来源：
ADVANCED DRUG DELIVERY REVIEWS | 2022年 / 191卷
基金：
美国国家卫生研究院;
关键词：
Cervicovaginal mucus; Microbicides; Preterm birth; Mucus penetrating particles; Reproductive tract cancer; CERVICAL-MUCUS PLUG; HUMAN CERVICOVAGINAL MUCUS; BACTERIAL VAGINOSIS; BARRIER PROPERTIES; POLYMERIC NANOPARTICLES; MOLECULAR-MECHANISM; SYNTHETIC-POLYMERS; MUCIN SECRETION; TRANSPORT; CELLS;
D O I：
10.1016/j.addr.2022.114543
中图分类号：
R9 [药学];
学科分类号：
1007 ;
摘要：
Vaginal drug delivery systems are often preferred for treating a variety of diseases and conditions of the female reproductive tract (FRT), as delivery can be more targeted with less systemic side effects. However, there are many anatomical and biological barriers to effective treatment via the vaginal route. Further, biocompatibility with the local tissue and microbial microenvironment is desired. A variety of in vitro and ex vivo models are described herein for evaluating the physicochemical properties and tox-icity profile of vaginal drug delivery systems. Deciding whether to utilize organoids in vitro or fresh human cervicovaginal mucus ex vivo requires careful consideration of the intended use and the formula-tion characteristics. Optimally, in vitro and ex vivo experimentation will inform or predict in vivo perfor-mance, and examples are given that describe utilization of a range of methods from in vitro to in vivo. Lastly, we highlight more advanced model systems for other mucosa as inspiration for the future in model development for the FRT. (c) 2022 Elsevier B.V. All rights reserved.
引用
收藏
页数：17
相关论文
共 50 条
  • [21] Modifying and Integrating in vitro and ex vivo Respiratory Models for Inhalation Drug Screening
    Cidem, Aylin
    Bradbury, Peta
    Traini, Daniela
    Ong, Hui Xin
    FRONTIERS IN BIOENGINEERING AND BIOTECHNOLOGY, 2020, 8
  • [22] Vaginal mucoadhesive drug delivery systems
    de Araujo Pereira, Raphaela Regina
    Bruschi, Marcos Luciano
    DRUG DEVELOPMENT AND INDUSTRIAL PHARMACY, 2012, 38 (06) : 643 - 652
  • [23] Gels as vaginal drug delivery systems
    das Neves, J.
    Bahia, M. F.
    INTERNATIONAL JOURNAL OF PHARMACEUTICS, 2006, 318 (1-2) : 1 - 14
  • [24] In Vitro, Ex Vivo, and In Vivo Models for the Study of Pemphigus
    Lotti, Roberta
    Atene, Claudio Giacinto
    Zanfi, Emma Dorotea
    Bertesi, Matteo
    Zanocco-Marani, Tommaso
    INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2022, 23 (13)
  • [25] Quantification of Cellular Drug Biodistribution Addresses Challenges in Evaluating In Vitro and In Vivo Encapsulated Drug Delivery
    Rodell, Christopher B.
    Baldwin, Paige
    Fernandez, Bianca
    Weissleder, Ralph
    Sridhar, Srinivas
    Dubach, John Matthew
    ADVANCED THERAPEUTICS, 2021, 4 (03)
  • [26] In vivo, in vitro and ex vivo models to assess pulmonary absorption and disposition of inhaled therapeutics for systemic delivery
    Sakagami, Masahiro
    ADVANCED DRUG DELIVERY REVIEWS, 2006, 58 (9-10) : 1030 - 1060
  • [27] New drug delivery systems: validation of transdermal in vitro models
    Daddona, P
    Holladay, L
    ANIMAL ALTERNATIVES, WELFARE, AND ETHICS, 1997, 27 : 857 - 859
  • [28] INTRAMURAL DELIVERY OF MARKER AGENT IN EX-VIVO AND IN-VIVO MODELS USING A NOVEL DRUG-DELIVERY SLEEVE
    KAPLAN, AV
    KERMODE, J
    GRANT, G
    KLEIN, E
    VETTE, RJ
    HINOHARA, T
    SIMPSON, JB
    JOURNAL OF THE AMERICAN COLLEGE OF CARDIOLOGY, 1994, : A187 - A187
  • [29] Polyester dendritic systems for drug delivery applications:: In vitro and in vivo evaluation
    De Jesús, OLP
    Ihre, HR
    Gagne, L
    Fréchet, JMJ
    Szoka, FC
    BIOCONJUGATE CHEMISTRY, 2002, 13 (03) : 453 - 461
  • [30] In vitro models for evaluating safety and efficacy of novel technologies for skin drug delivery
    Planz, Viktoria
    Lehr, Claus-Michael
    Windbergs, Maike
    JOURNAL OF CONTROLLED RELEASE, 2016, 242 : 89 - 104
12345